Antigen targeting to endosomal pathway in dendritic cell vaccination activates regulatory T cells and attenuates tumor immunity

被引:20
作者
Maksimow, Mikael
Miiluniemi, Mari
Marttila-Ichihara, Fumiko
Jalkanen, Sirpa
Hanninen, Arno
机构
[1] Univ Turku, MediCity Res Lab, Turku, Finland
[2] Univ Turku, Dept Med Microbiol, Turku, Finland
[3] Natl Publ Hlth Inst, Dept Turku, Turku, Finland
[4] Turku Grad Sch Biomed Sci, Turku, Finland
关键词
D O I
10.1182/blood-2005-11-008615
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Lymphoma cells are malignant cells of the T- or B-cell lineage that often express many surface markers inappropriately, yet are not recognized as abnormal by the immune system. We modeled this situation by inoculating ovalbumin-expressing E.G7-OVA lymphoma cells into mice that expressed ovalbumin as a self antigen in pancreatic islets, and investigated the efficacy of dendritic cell (DC) vaccination in these mice. Although vaccination with DC-expressing ovalbumin induced strong cytotoxic T-cell immunity, which led to clearance of E.G7-OVA lymphoma cells in naive C57BL/6 mice, DC vaccination was ineffective in mice expressing ovalbumin as a self antigen. Antigen modification to increase its processing via the endosomal processing pathway dramatically increased CD4 T-cell activation but paradoxically, impaired the protective effect of DC vaccination even in naive mice. Depletion of CD25(+) T cells (regulatory T cells [Tregs]) prior to vaccination restored the efficacy of DC vaccination and allowed eradication of lymphoma also in mice expressing ovalbumin as a self antigen. We conclude that lymphoma cells may be eradicated using DC vaccination if activation of CD25(+) Tregs is simultaneously inhibited, and that intentionally enhanced endosomal antigen processing in DC vaccines may shift the balance from CD4 T-cell help toward stimulation of Tregs.
引用
收藏
页码:1298 / 1305
页数:8
相关论文
共 41 条
[1]  
BENNETT SR, 1997, J EXP MED, V186, P165
[2]   Genetic approaches for the induction of a CD4+ T cell response in cancer immunotherapy [J].
Bonehill, A ;
Heirman, C ;
Thielemans, K .
JOURNAL OF GENE MEDICINE, 2005, 7 (06) :686-695
[3]   Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules [J].
Bonehill, A ;
Heirman, C ;
Tuyaerts, S ;
Michiels, A ;
Breckpot, K ;
Brasseur, F ;
Zhang, Y ;
van der Bruggen, P ;
Thielemans, K .
JOURNAL OF IMMUNOLOGY, 2004, 172 (11) :6649-6657
[4]   A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory [J].
Bourgeois, C ;
Rocha, B ;
Tanchot, C .
SCIENCE, 2002, 297 (5589) :2060-2063
[5]   Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity [J].
Celluzzi, CM ;
Mayordomo, JI ;
Storkus, WJ ;
Lotze, MT ;
Falo, LD .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (01) :283-287
[6]   Dendritic cell immunization route determines CD8+ T cell trafficking to inflamed skin:: Role for tissue microenvironment and dendritic cells in establishment of T cell-homing subsets [J].
Dudda, JC ;
Simon, JC ;
Martin, S .
JOURNAL OF IMMUNOLOGY, 2004, 172 (02) :857-863
[7]   THERAPY OF DISSEMINATED MURINE LEUKEMIA WITH CYCLOPHOSPHAMIDE AND IMMUNE LYT-1+,2- T-CELLS - TUMOR-ERADICATION DOES NOT REQUIRE PARTICIPATION OF CYTO-TOXIC T-CELLS [J].
GREENBERG, PD ;
KERN, DE ;
CHEEVER, MA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1985, 161 (05) :1122-1134
[8]   INTERLEUKIN-7 INDUCES CD4+ T-CELL-DEPENDENT TUMOR REJECTION [J].
HOCK, H ;
DORSCH, M ;
DIAMANTSTEIN, T ;
BLANKENSTEIN, T .
JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 174 (06) :1291-1298
[9]   Targeting tumor cells [J].
Houshmand, P ;
Zlotnik, A .
CURRENT OPINION IN CELL BIOLOGY, 2003, 15 (05) :640-644
[10]   The central role of CD4+ T cells in the antitumor immune response [J].
Hung, K ;
Hayashi, R ;
Lafond-Walker, A ;
Lowenstein, C ;
Pardoll, D ;
Levitsky, H .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (12) :2357-2368